Xenon Pharmaceuticals Inc.

Address: 3650 Gilmore Way

Sponsor Overview

assignment

Specializations

Epilepsy and Seizure Disorders

Clinical research is centered on focal epilepsy, including adult focal (partial onset) epilepsy and focal-onset seizures, with additional attention to primary generalized tonic-clonic seizures.

Focal-onset seizures
Adult focal epilepsy
Primary generalized tonic-clonic seizures

These studies reflect sustained interest in seizure reduction and symptom control across multiple forms of epilepsy.

Major Depressive Disorder

The sponsor also funds research in major depressive disorder, focusing on treatment options for depressive symptoms and overall mood improvement.

Major depressive disorder
Depressive symptoms

This area extends the company’s interest in central nervous system conditions beyond seizure-related disease.

Bipolar Depression

Another active therapeutic area is bipolar depression, including depressive episodes associated with bipolar I or II disorder.

Bipolar I disorder
Bipolar II disorder
Depressive episodes

Research in this domain addresses mood disorder management within the broader spectrum of affective disorders.

Neurology and Central Nervous System Therapeutics

The overall pipeline is strongly oriented toward neurology, with overlapping programs in seizure control and mood disorders that fall within central nervous system therapeutics.

Neurology
Central nervous system disorders
Seizure control
Mood disorders

Research activity spans multiple countries and sites, supporting development efforts in both epilepsy and psychiatric indications.

Sponsored Trials

Trial Name	Country	Status
A Long-term, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Azetukalner in Patients with Bipolar I or II Depression	Bulgaria France Germany Spain	Not Yet Recruiting
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)	Austria Belgium Bulgaria Croatia Czechia Finland France Germany Hungary Ireland Italy Latvia Poland Portugal Spain The Netherlands	Recruiting
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Azetukalner as Adjunctive Therapy in Focal-Onset Seizures	Bulgaria Czechia Germany Ireland Italy Latvia Poland Portugal Spain	Not Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Azetukalner in Patients with Bipolar Depression	Bulgaria Germany Poland Spain	Recruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Azetukalner in Patients with Moderate-to-Severe Major Depressive Disorder	Czechia Finland Germany Poland Romania Slovakia Spain	Recruiting
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures	Austria Belgium Bulgaria Croatia Czechia Finland France Germany Hungary Italy Poland Portugal Spain The Netherlands	Recruiting
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)	Austria Belgium Bulgaria Croatia Czechia France Germany Italy Poland Portugal Spain The Netherlands	Recruiting
Evaluation of the Safety, Tolerability, and Efficacy of Azetukalner as Adjunctive Therapy in Adults with Focal-Onset Epilepsy: A Randomized, Double-Blind, Placebo-Controlled Study	Germany Italy Spain	Not Recruiting
Long‑Term Open‑Label Safety, Tolerability, and Efficacy of Azetukalner (XPF‑010) in Adults with Major Depressive Disorder	Finland Germany Poland Romania Slovakia Spain	Recruiting

Data & Insights

science

Molecule Portfolio

Compounds under investigation

Exclusive Molecules

out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub

Site Partnerships

Collaboration with research centres

80%

Return partnership rate

98 of 123 sites collaborated multiple times

This sponsor has worked with 123 sites across their trial portfolio.

Therapeutic Focus

1.
Nervous System Diseases5 trials
449 other sponsors
2.
Mental Disorders4 trials
150 other sponsors

Partnered Research Centres

123 centres

location_city

assignment2

Altavita centar j.d.o.o.

Address: Vrhovec 98, Zagreb, 10000 Zagreb

Learn morearrow_forward

location_city

assignment7

Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Address: Biocruces Bizkaia Health Research Center Institute, Neurology Sevice- Cruces University Hospital, Edificio Biocruces 1-4a Planta Grupo de Enfermedades Neurodegenerativas, Plaza Cruces s/n, 48903 Barakaldo

Learn morearrow_forward

location_city

assignment66

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari